Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
712 North Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner, WHITE, ASHLEY TAYLOR, and 1 distinct art unit. WHITE, ASHLEY TAYLOR is the busiest examiner with 1 pending action, which is the only active matter for the company. The prosecution is currently limited to this single interaction within the biotech field, allowing for a concentrated and efficient legal strategy.
The reliance on 1 distinct examiner for the 1 pending office action means that the company's immediate success depends on navigating the specific preferences of WHITE, ASHLEY TAYLOR. Because the case is situated in 1 distinct art unit, practitioners can focus their research on the specific technical guidelines relevant to that group. This centralized structure minimizes the complexity of managing multiple examiners but also places significant weight on the outcome of this single biotechnology matter. Effective prosecution will require a strategy that directly addresses the 1 distinct art unit's standards and the examiner's specific feedback.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WHITE, ASHLEY TAYLOR | 1 | 23.8% | +36.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18019733 | METHODS AND COMPOSITIONS FOR PROTEASE REPORTER ASSAYS AND MODULATORS | WHITE, ASHLEY TAYLOR | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18019733 | METHODS AND COMPOSITIONS FOR PROTEASE REPORTER ASSAYS AND MODULATORS | WHITE, ASHLEY TAYLOR | — |
| Art Unit | Apps |
|---|---|
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18019733 | METHODS AND COMPOSITIONS FOR PROTEASE REPORTER ASSAYS AND MODULATORS | WHITE, ASHLEY TAYLOR | 1653 | §103§112 | Non-Final OA | — | Pending | Feb 03, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial712 North Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Ashley Taylor White has the most, with 1 of 712 North Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
